The only touchless, painless treatment of Onychomycosis.
Since 1996, Erchonia, the manufacturer of Lunula, has been committed to fully elucidating the medical utility of low-level laser therapy through rigorous clinical studies. For over a decade, Erchonia has studied the clinical utility of low-level laser
devices for the treatment of numerous medical ailments, and their recent device, Lunula, looks to revolutionise the way the medical community treats onychomycosis.
Lunula has been markedly studied – from the early in-vitro analysis to the extensive in-vivo studies – and its clinical utility to treat painful and unsightly toenail infections has been substantiated.
The unique dual-diode approach of Lunula effectively targets the causative infectious agent while fortifying the body's natural defense mechanisms. This multifaceted approach is the first of its kind, providing patients with a truly effective, yet safe, treatment for onychomycosis..
Lunula combines two therapeutically beneficial wavelengths: 405 and 635nm. Each wavelength is capable of stimulating a specific cascade to effectively and safely treat onychomycosis. Both wavelengths are enriched by a proprietary, rotating line-generated beam; a unique delivery mechanism that maximises photon concentration and treatment surface area— ensuring that all infected toes are properly treated. As a result, the Lunula provides a treatment absent of any adverse events while inducing key pathways to effectively address unsightly onychomycosis.
The 635nm wavelength stimulates cytochrome c oxidsase (CCO), an important enzyme necessary for the production of adenosine triphosphate (ATP) and reactive oxygen species (ROS). Increased ATP activates PI3 kinase/eNOS signaling pathways, which increases nitric oxide (NO) production. NO is critical for new blood vessel formation increasing nutrient delivery and infiltration of immunological cells. Additionally, NO is a powerful antimicrobial agent, and will help destroy the infectious agent. For resident macrophages and neutrophils, two types of immune cells, the increased production of ROS is quickly converted into cytotoxic hydrogen peroxide (H2O2), which is used by the immune cells to destroy onychomycosis-causing fungus.
The 405nm wavelength targets NADPH oxidase (NOX), a membrane bound enzyme, and increases NOX's production of ROS, which can be converted into H2O2. As H2O2 starts to degrade the fungal cell wall and membrane fungi function and behavior will be greatly impaired. This can result in fungal death. Additionally, degradation of the fungi membrane and cell wall will increase fungal susceptibility to the body's immune attack.
two therapeutically beneficial wavelengths
The production of ROS is crucial for the successful treatment of onychomycosis. The application of 405nm has been reported to significantly increase the production of ROS and activate key secondary cascades to weaken fungi defense against the body's immune response, which in turn, kills the fungus. When compared to other wavelengths, 405nm yields the highest production of ROS.
Peripheral blood flow impairment can affect the body's endogenous immune response to the colonising fungus. Without the infiltration of leukocytes, monocytes, and macrophage, the infectious agent is able to spread along the nail plate and bed. The 635nm wavelength has been proven to increase peripheral blood by stimulating key pathways responsible for angiogenesis (new blood vessel formation). Increased blood flow provides greater nutrient delivery to tissues for rejuvenation and enables immune cells to infiltrate the tissue to destroy the fungus. The images below demonstrate the improved blood flow benefit of the 635nm wavelength.